|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0030705,
umls-concept:C0040808,
umls-concept:C0087111,
umls-concept:C0439230,
umls-concept:C0537439,
umls-concept:C0871261,
umls-concept:C1274040,
umls-concept:C1608294,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2267040,
umls-concept:C2698872,
umls-concept:C2911692
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2006-2-14
|
|
pubmed:abstractText |
Early virological response to antiretroviral therapy is predictive of long-term treatment outcome in therapy-naive patients. In treatment-experienced patients, such correlations are less well defined, because initial responses may be less pronounced and transient because of accumulated cross-resistance to prior therapies. Our objectives were to explore how the virological and immunological status of treatment-experienced patients at an early time point (week 12) during enfuvirtide-based therapy predicted their responses at weeks 24, 48, and 96 in the T-20 versus Optimized Regimen Only (TORO) trials.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1537-6591
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
15
|
|
pubmed:volume |
42
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
870-7
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16477567-Clinical Trials, Phase III as Topic,
pubmed-meshheading:16477567-HIV Envelope Protein gp41,
pubmed-meshheading:16477567-HIV Fusion Inhibitors,
pubmed-meshheading:16477567-HIV Infections,
pubmed-meshheading:16477567-HIV-1,
pubmed-meshheading:16477567-Humans,
pubmed-meshheading:16477567-Peptide Fragments,
pubmed-meshheading:16477567-Randomized Controlled Trials as Topic,
pubmed-meshheading:16477567-Regression Analysis,
pubmed-meshheading:16477567-Time Factors,
pubmed-meshheading:16477567-Treatment Outcome,
pubmed-meshheading:16477567-Viral Load
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials.
|
|
pubmed:affiliation |
University Hospital, Nantes, France. francois.raffi@chu-nantes.fr
|
|
pubmed:publicationType |
Journal Article
|
